source
- Positive data from Bristol Myers in multiple myeloma and Pfizer in lung cancer unveiled at ASCOAt the American Society of Clinical Oncology (ASCO) meeting, Bristol Myers Squibb presented early-stage results that showed a favorable response in a multiple myeloma trial. The data suggest the in…
- Agios halts development of tebapivat for low-risk MDS after disappointing Phase 2b dataAgios Pharmaceuticals announced it will discontinue development of its pyruvate kinase activator tebapivat for patients with low-risk myelodysplastic syndromes (MDS). The decision follows the relea…